Pacific Biosciences of California PACB Business Segments — Gain on debt restructuring
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:GainsLossesOnRestructuringOfDebt.
The official record: Pacific Biosciences of California’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's business segments — gain on debt restructuring.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's business segments — gain on debt restructuring?
- Pacific Biosciences of California (PACB) reported business segments — gain on debt restructuring of $0 in Q4 2025.
- How has Pacific Biosciences of California's business segments — gain on debt restructuring changed year-over-year?
- Pacific Biosciences of California's business segments — gain on debt restructuring decreased by 100.0% year-over-year, from $38.6M to $0.
- What does business segments — gain on debt restructuring mean?
- This represents the financial gain realized by the reportable segment when debt obligations are modified or settled under terms more favorable than the original carrying value. Such gains often arise from negotiated settlements or debt-for-equity swaps that reduce the total liability burden. This metric highlights the impact of successful balance sheet management on the segment's reported earnings.